Looking to topple Pfizer's Prevnar 13 dynasty, Merck claims another win for its 'breakthrough' pneumococcal conjugate vaccine

Three months after winning the FDA’s breakthrough therapy designation for its bigger/better pneumococcal conjugate vaccine candidate aimed at toppling Pfizer’s Prevnar 13 megablockbuster bestseller, Merck is back with a batch of upbeat Phase II data from their big clinical program.